Financing ·
Aclaris Therapeutics prices $46.7M equity offering of common stock and pre-funded warrants at $3.50
ACRSAclaris Therapeutics, Inc.
Aclaris Therapeutics entered into an underwriting agreement to sell 7,785,714 shares of common stock and pre-funded warrants for 6,500,000 additional shares. The offering price is set at $3.50 per share of common stock and $3.49999 per pre-funded warrant. Net proceeds are estimated at approximately $46.7 million after deducting underwriting discounts and expenses. Closing is expected on October 28, 2026. The company operates in the biopharmaceutical industry.